TNBC, defined by the absence of ER, PR and HER2 expression, accounts for approximately 15%–20% of breast cancer cases and presents a significant clinical challenge due to its resistance to conventional endocrine and HER2‐targeted therapies [2]. Here, ERBB2 is linked to breast carcinoma.